Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2022 Redeem voucher Abstracts, 5–7 May 2022, Gliwice

open access

Vol 69, No 3 (2018)
Original paper
Submitted: 2017-10-25
Accepted: 2018-01-08
Published online: 2018-05-08
View PDF Download PDF file Supp./Additional Files [1]
Get Citation

Elevated serum lipocalin 2 levels are associated with indexes of both glucose and bone metabolism in type 2 diabetes mellitus

Wei Wang, Shandong Ye, Liting Qian, Yan Xing, An Ren, Chao Chen, Sumei Li, Jiang Xu, Qian Liu, Lin Dong, Chunchun Xiao, Wan Zhou
DOI: 10.5603/EP.a2018.0030
·
Pubmed: 29952418
·
Endokrynol Pol 2018;69(3):276-282.

open access

Vol 69, No 3 (2018)
Original Paper
Submitted: 2017-10-25
Accepted: 2018-01-08
Published online: 2018-05-08

Abstract

Introduction: The role of lipocalin 2 (LCN2) in type 2 diabetes mellitus (T2DM) needs to be fully elucidated. Moreover, bone has been demonstrated to modulate glucose metabolism via LCN2. We thus performed this study to investigate the associations of LCN2 with indexes of glucose metabolism in T2DM. The associations of LCN2 with bone metabolism were examined concurrently. Material and methods: Total 288 Chinese Han subjects entered in this study including 146 patients with T2DM and 142 subjects with normal glucose tolerance. Insulin resistance was assessed by HOMA-IR and

Abstract

Introduction: The role of lipocalin 2 (LCN2) in type 2 diabetes mellitus (T2DM) needs to be fully elucidated. Moreover, bone has been demonstrated to modulate glucose metabolism via LCN2. We thus performed this study to investigate the associations of LCN2 with indexes of glucose metabolism in T2DM. The associations of LCN2 with bone metabolism were examined concurrently. Material and methods: Total 288 Chinese Han subjects entered in this study including 146 patients with T2DM and 142 subjects with normal glucose tolerance. Insulin resistance was assessed by HOMA-IR and

Full Text:

View PDF Download PDF file Supp./Additional Files [1]
Get Citation

Keywords

lipocalin 2, type 2 diabetes mellitus, bone mineral density

Supp./Additional Files (1)
Title page
Download
14KB
About this article
Title

Elevated serum lipocalin 2 levels are associated with indexes of both glucose and bone metabolism in type 2 diabetes mellitus

Journal

Endokrynologia Polska

Issue

Vol 69, No 3 (2018)

Article type

Original paper

Pages

276-282

Published online

2018-05-08

Page views

3078

Article views/downloads

1366

DOI

10.5603/EP.a2018.0030

Pubmed

29952418

Bibliographic record

Endokrynol Pol 2018;69(3):276-282.

Keywords

lipocalin 2
type 2 diabetes mellitus
bone mineral density

Authors

Wei Wang
Shandong Ye
Liting Qian
Yan Xing
An Ren
Chao Chen
Sumei Li
Jiang Xu
Qian Liu
Lin Dong
Chunchun Xiao
Wan Zhou

References (40)
  1. Kjeldsen L, Cowland JB, Borregaard N. Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta. 2000; 1482(1-2): 272–283.
    PubMed
  2. Park M, Hsu CY, Go AS, et al. Chronic Renal Insufficiency Cohort (CRIC) Study Investigators, CKD Biomarkers Consortium. Urine Kidney Injury Biomarkers and Risks of Cardiovascular Disease Events and All-Cause Death: The CRIC Study. Clin J Am Soc Nephrol. 2017; 12(5): 761–771.
    CrossRefPubMed
  3. Castillo-Rodriguez E, Fernandez-Prado R, Martin-Cleary C, et al. Kidney Injury Marker 1 and Neutrophil Gelatinase-Associated Lipocalin in Chronic Kidney Disease. Nephron. 2017; 136(4): 263–267.
    CrossRefPubMed
  4. Gomez-Chou SB, Swidnicka-Siergiejko AK, Badi N, et al. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. Cancer Res. 2017; 77(10): 2647–2660.
    CrossRefPubMed
  5. Sporek M, Dumnicka P, Gala-Błądzińska A, et al. Determination of serum neutrophil gelatinase-associated lipocalin at the early stage of acute pancreatitis. Folia Med Cracov. 2016; 56(2): 5–16.
    PubMed
  6. Al Nimer F, Elliott C, Bergman J, et al. Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination. Neurol Neuroimmunol Neuroinflamm. 2016; 3(1): e191.
    CrossRefPubMed
  7. Moschen AR, Adolph TE, Gerner RR, et al. Lipocalin-2: A Master Mediator of Intestinal and Metabolic Inflammation. Trends Endocrinol Metab. 2017; 28(5): 388–397.
    CrossRefPubMed
  8. Costa D, Lazzarini E, Canciani B, et al. Altered bone development and turnover in transgenic mice over-expressing lipocalin-2 in bone. J Cell Physiol. 2013; 228(11): 2210–2221.
    CrossRefPubMed
  9. Rucci N, Capulli M, Piperni SG, et al. Lipocalin 2: a new mechanoresponding gene regulating bone homeostasis. J Bone Miner Res. 2015; 30(2): 357–368.
    CrossRefPubMed
  10. Mosialou I, Shikhel S, Liu JM, et al. MC4R-dependent suppression of appetite by bone-derived lipocalin 2. Nature. 2017; 543(7645): 385–390.
    CrossRefPubMed
  11. Wang Yu, Lam KSL, Kraegen EW, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem. 2007; 53(1): 34–41.
    CrossRefPubMed
  12. Huang Y, Yang Z, Ye Zi, et al. Lipocalin-2, glucose metabolism and chronic low-grade systemic inflammation in Chinese people. Cardiovasc Diabetol. 2012; 11: 11.
    CrossRefPubMed
  13. Rashad NM, El-Shal AS, Etewa RL, et al. Lipocalin-2 expression and serum levels as early predictors of type 2 diabetes mellitus in obese women. IUBMB Life. 2017; 69(2): 88–97.
    CrossRefPubMed
  14. Auguet T, Quintero Y, Terra X, et al. Upregulation of lipocalin 2 in adipose tissues of severely obese women: positive relationship with proinflammatory cytokines. Obesity (Silver Spring). 2011; 19(12): 2295–2300.
    CrossRefPubMed
  15. Liu X, Hamnvik OPR, Petrou M, et al. Circulating lipocalin 2 is associated with body fat distribution at baseline but is not an independent predictor of insulin resistance: the prospective Cyprus Metabolism Study. Eur J Endocrinol. 2011; 165(5): 805–812.
    CrossRefPubMed
  16. Wallenius V, Elias E, Bergstrom GML, et al. The lipocalins retinol-binding protein-4, lipocalin-2 and lipocalin-type prostaglandin D2-synthase correlate with markers of inflammatory activity, alcohol intake and blood lipids, but not with insulin sensitivity in metabolically healthy 58-year-old Swedish men. Exp Clin Endocrinol Diabetes. 2011; 119(2): 75–80.
    CrossRefPubMed
  17. Xiao Y, Liu L, Xu A, et al. Circulating lipocalin-2 and retinol-binding protein 4 are associated with intima-media thickness and subclinical atherosclerosis in patients with type 2 diabetes. PLoS One. 2013; 8(6): e66607.
    CrossRefPubMed
  18. El-Mesallamy HO, Hamdy NM, Sallam AaM. Effect of obesity and glycemic control on serum lipocalins and insulin-like growth factor axis in type 2 diabetic patients. Acta Diabetol. 2013; 50(5): 679–685.
    CrossRefPubMed
  19. Gala-Błądzińska A, Dumnicka P, Kuśnierz-Cabala B, et al. Urinary Neutrophil Gelatinase-Associated Lipocalin Is Complementary to Albuminuria in Diagnosis of Early-Stage Diabetic Kidney Disease in Type 2 Diabetes. Biomed Res Int. 2017; 2017: 4691389.
    CrossRefPubMed
  20. Luo Y, Ma X, Pan X, et al. Serum lipocalin-2 levels are positively associated with not only total body fat but also visceral fat area in Chinese men. Medicine (Baltimore). 2016; 95(30): e4039.
    CrossRefPubMed
  21. Ni J, Ma X, Zhou Mi, et al. Serum lipocalin-2 levels positively correlate with coronary artery disease and metabolic syndrome. Cardiovasc Diabetol. 2013; 12: 176.
    CrossRefPubMed
  22. Zeng G, Jia CW, Liu J, et al. Lipocalin-2 test in distinguishing acute lung injury cases from septic mice without acute lung injury. Chin Med Sci J. 2014; 29(2): 65–77.
    PubMed
  23. Chung JO, Park SY, Cho DH, et al. Plasma neutrophil gelatinase-associated lipocalin levels are positively associated with diabetic retinopathy in patients with Type 2 diabetes. Diabet Med. 2016; 33(12): 1649–1654.
    CrossRefPubMed
  24. Sołtysiak J, Skowrońska B, Fichna P, et al. Neutrophil gelatinase-associated lipocalin and Cathepsin L as early predictors of kidney dysfunction in children with type 1 diabetes. Endokrynol Pol. 2014; 65(6): 479–484.
    CrossRefPubMed
  25. Żyłka A, Gala-Błądzińska A, Dumnicka P, et al. Is Urinary NGAL Determination Useful for Monitoring Kidney Function and Assessment of Cardiovascular Disease? A 12-Month Observation of Patients with Type 2 Diabetes. Dis Markers. 2016; 2016: 8489543.
    CrossRefPubMed
  26. Zhang Y, Foncea R, Deis JA, et al. Lipocalin 2 expression and secretion is highly regulated by metabolic stress, cytokines, and nutrients in adipocytes. PLoS One. 2014; 9(5): e96997.
    CrossRefPubMed
  27. Yan QW, Yang Q, Mody N, et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes. 2007; 56(10): 2533–2540.
    CrossRefPubMed
  28. Zand H, Morshedzadeh N, Naghashian F. Signaling pathways linking inflammation to insulin resistance. Diabetes Metab Syndr. 2017; 11 Suppl 1: S307–S309.
    CrossRefPubMed
  29. Lee BC, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta. 2014; 1842(3): 446–462.
    CrossRefPubMed
  30. Chang SY, Kim DB, Ko SH, et al. Induction mechanism of lipocalin-2 expression by co-stimulation with interleukin-1β and interferon-γ in RINm5F beta-cells. Biochem Biophys Res Commun. 2013; 434(3): 577–583.
    CrossRefPubMed
  31. Chang SY, Kim DB, Ko SH, et al. The level of nitric oxide regulates lipocalin-2 expression under inflammatory condition in RINm5F beta-cells. Biochem Biophys Res Commun. 2016; 476(1): 7–14.
    CrossRefPubMed
  32. Zhang J, Wu Y, Zhang Y, et al. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol. 2008; 22(6): 1416–1426.
    CrossRefPubMed
  33. Xiang Y, Zhou P, Li X, et al. Heterogeneity of altered cytokine levels across the clinical spectrum of diabetes in China. Diabetes Care. 2011; 34(7): 1639–1641.
    CrossRefPubMed
  34. Wu C, Wang Q, Lv C, et al. The changes of serum sKlotho and NGAL levels and their correlation in type 2 diabetes mellitus patients with different stages of urinary albumin. Diabetes Res Clin Pract. 2014; 106(2): 343–350.
    CrossRefPubMed
  35. Sporek M, Gala-Błądzińska A, Dumnicka P, et al. Urine NGAL is useful in the clinical evaluation of renal function in the early course of acute pancreatitis. Folia Med Cracov. 2016; 56(1): 13–25.
    PubMed
  36. Jia P, Bao L, Chen H, et al. Risk of low-energy fracture in type 2 diabetes patients: a meta-analysis of observational studies. Osteoporos Int. 2017; 28(11): 3113–3121.
    CrossRefPubMed
  37. Iki M, Fujita Y, Kouda K, et al. Hyperglycemia is associated with increased bone mineral density and decreased trabecular bone score in elderly Japanese men: The Fujiwara-kyo osteoporosis risk in men (FORMEN) study. Bone. 2017; 105: 18–25.
    CrossRefPubMed
  38. Rendina-Ruedy E, Graef JL, Lightfoot SA, et al. Impaired glucose tolerance attenuates bone accrual by promoting the maturation of osteoblasts: Role of Beclin1-mediated autophagy. Bone Rep. 2016; 5: 199–207.
    CrossRefPubMed
  39. Zhang W, Shen X, Wan C, et al. Effects of insulin and insulin-like growth factor 1 on osteoblast proliferation and differentiation: differential signalling via Akt and ERK. Cell Biochem Funct. 2012; 30(4): 297–302.
    CrossRefPubMed
  40. Levinger I, Seeman E, Jerums G, et al. Glucose-loading reduces bone remodeling in women and osteoblast function in vitro. Physiol Rep. 2016; 4(3).
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl